Acrivon Therapeutics, Inc. · NASDAQ:ACRV

Citadel Advisors LLC reported a 5.50% stake in Acrivon Therapeutics, Inc. (Schedule 13G)

Event Nov 14, 2025 · Filed Nov 21, 2025

Citadel Advisors LLC reported a 5.50% stake in Acrivon Therapeutics, Inc., 1,721,867 shares, as a passive investor on Nov 14, 2025. Filed Nov 21, 2025 (Schedule 13G).

Stake
5.50%
Shares
1,721,867
Intent
Passive
What changed
Crossed above 5%
Filed together
7 holders

The filing in full

HolderStakeShares
Citadel Advisors LLC4.90%1,541,326
Citadel Advisors Holdings LP4.90%1,541,326
Citadel GP LLC4.90%1,541,326
Citadel Securities LLC0.60%180,541
Citadel Securities Group LP0.60%180,541
Citadel Securities GP LLC0.60%180,541
Kenneth Griffin5.50%1,721,867

Source

View original at SEC

Related